Hutchmed's Partner Takeda Pharmaceutical Gets Go-Ahead to Produce, Market Colorectal Cancer Drug in Japan

MT Newswires Live

2024/09/24

Pharmaceutical firm Hutchmed's (HKG:0013) partner Takeda Pharmaceutical (TYO:4502) has received regulatory approval to manufacture and market FRUZAQLA in Japan, a Tuesday bourse filing said.

The drug is used to treat advanced or recurrent metastatic colorectal cancer that is neither curable nor resectable, and that has progressed after chemotherapy.

Shares of Hutchmed closed nearly 3% higher on Tuesday.

Price (HKD): $26.65, Change: $+0.75, Percent Change: +2.90%

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2469549469"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2469549469\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2469549469?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-24 18:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2469549469","market":"nz","top_or_hot":-1,"title":"Hutchmed's Partner Takeda Pharmaceutical Gets Go-Ahead to Produce, Market Colorectal Cancer Drug in Japan","media":"MT Newswires Live","content":"<html><body><p> Pharmaceutical firm Hutchmed's (HKG:0013) partner Takeda Pharmaceutical (TYO:4502) has received regulatory approval to manufacture and market FRUZAQLA in Japan, a Tuesday bourse filing said.</p><p>The drug is used to treat advanced or recurrent metastatic colorectal cancer that is neither curable nor resectable, and that has progressed after chemotherapy.</p><p>Shares of Hutchmed closed nearly 3% higher on Tuesday.</p><p>Price (HKD): $26.65, Change: $+0.75, Percent Change: +2.90%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hutchmed's Partner Takeda Pharmaceutical Gets Go-Ahead to Produce, Market Colorectal Cancer Drug in Japan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHutchmed's Partner Takeda Pharmaceutical Gets Go-Ahead to Produce, Market Colorectal Cancer Drug in Japan\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-09-24 18:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Pharmaceutical firm Hutchmed's (HKG:0013) partner Takeda Pharmaceutical (TYO:4502) has received regulatory approval to manufacture and market FRUZAQLA in Japan, a Tuesday bourse filing said.</p><p>The drug is used to treat advanced or recurrent metastatic colorectal cancer that is neither curable nor resectable, and that has progressed after chemotherapy.</p><p>Shares of Hutchmed closed nearly 3% higher on Tuesday.</p><p>Price (HKD): $26.65, Change: $+0.75, Percent Change: +2.90%</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HKD","symbol_name":"尚乘數科","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2469549469","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2469549469","pubTimestamp":1727175217,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pharmaceutical firm Hutchmed's (HKG:0013) partner Takeda Pharmaceutical (TYO:4502) has received regulatory approval to manufacture and market FRUZAQLA in Japan, a Tuesday bourse filing said.The drug i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HKD":"尚乘数科","BK1191":"制药","BK1588":"回港中概股","BK4526":"热门中概股","BK4588":"碎股","BK4023":"应用软件","BK1587":"次新股","00013":"和黄医药","BK4585":"ETF&股票定投概念"},"translate_title":"和黄医药合作伙伴武田制药获准在日本生产和销售结直肠癌药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"00013":1},"content_text":"Pharmaceutical firm Hutchmed's (HKG:0013) partner Takeda Pharmaceutical (TYO:4502) has received regulatory approval to manufacture and market FRUZAQLA in Japan, a Tuesday bourse filing said.The drug is used to treat advanced or recurrent metastatic colorectal cancer that is neither curable nor resectable, and that has progressed after chemotherapy.Shares of Hutchmed closed nearly 3% higher on Tuesday.Price (HKD): $26.65, Change: $+0.75, Percent Change: +2.90%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}